MARKET

RNA

RNA

Avidity Biosciences, Inc.
NASDAQ
25.52
+0.85
+3.45%
After Hours: 25.40 -0.12 -0.47% 19:36 03/28 EDT
OPEN
24.56
PREV CLOSE
24.67
HIGH
25.95
LOW
24.50
VOLUME
1.23M
TURNOVER
0
52 WEEK HIGH
26.24
52 WEEK LOW
4.825
MARKET CAP
2.04B
P/E (TTM)
-8.7800
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at RNA last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at RNA last week (0311-0315)?
Weekly Report · 03/18 10:45
Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
Avidity Biosciences has a blockbuster product in deldesiran for myotonic dystrophy type 1 (DM1) Cantor Fitzgerald has initiated coverage on the company. The analyst says Avidity has accumulated extensive biomarker and clinical data. The company has a strong management team and a proven platform.
Benzinga · 03/14 19:29
Avidity Biosciences Initiated at Overweight by Cantor Fitzgerald
Dow Jones · 03/14 11:47
Avidity Biosciences Price Target Announced at $60.00/Share by Cantor Fitzgerald
Dow Jones · 03/14 11:47
Cantor Fitzgerald Initiates Coverage On Avidity Biosciences with Overweight Rating, Announces Price Target of $60
Benzinga · 03/14 11:37
Weekly Report: what happened at RNA last week (0304-0308)?
Weekly Report · 03/11 10:43
Avidity Biosciences: Strong Buy Rating Amidst Positive Clinical Developments and Price Target Surge
TipRanks · 03/07 04:25
More
About RNA
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.

Webull offers Avidity Biosciences Inc stock information, including NASDAQ: RNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNA stock methods without spending real money on the virtual paper trading platform.